4.2 Review

Chronic Thromboembolic Pulmonary Hypertension

期刊

HEART FAILURE CLINICS
卷 14, 期 3, 页码 339-+

出版社

ELSEVIER SCIENCE INC
DOI: 10.1016/j.hfc.2018.02.009

关键词

Chronic thromboembolic pulmonary hypertension; CTEPH; Pulmonary hypertension; Pulmonary embolism; Chronic thromboembolism; Pulmonary endarterectomy; Pulmonary artery balloon angioplasty

资金

  1. Actelion
  2. Bayer
  3. Gilead
  4. Ikaria
  5. Lung International
  6. National Heart, Lung and Blood Institute - National Institutes of Health
  7. United Therapeutics
  8. National Heart, Lung and Blood Institute - National Institutes of Health [HL123965]

向作者/读者索取更多资源

Chronic thromboembolic pulmonary hypertension (CTEPH) is a distinct type of pulmonary hypertensive disease, characterized by incomplete or abnormal resolution of acute pulmonary embolism such that residual emboli become organized and fibrotic. CTEPH can occur in patients without a prior history of venous thromboembolism and is diagnosed based on precapillary pulmonary hypertension on catheterization of the right side of the heart with evidence of chronic emboli on ventilation/perfusion scan, chest imaging, or pulmonary angiogram. Pulmonary endarterectomy (PEA) is often curative and results in improved survival. In patients for whom PEA is not feasible, medical therapy has been effective in improving hemodynamics and functional capacity.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.2
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据